Understand the source comparison
How to Use Peptides for Eczema: Treatment Protocol Comparison
Primary Mechanism Inhibits S. aureus biofilm, reduces bacterial load by 85–90% within 14 days Stimulates TGF-β and collagen synthesis, increases ceramide production by 34% Suppresses inflammatory cytokine release, reduces visible inflammation within 48 hours L
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Primary Mechanism
- Inhibits S. aureus biofilm, reduces bacterial load by 85–90% within 14 days
- Stimulates TGF-β and collagen synthesis, increases ceramide production by 34%
- Suppresses inflammatory cytokine release, reduces visible inflammation within 48 hours
- LL-37 addresses infection; GHK-Cu rebuilds barrier; steroids suppress symptoms without correcting deficiency
- Application Frequency
- Twice daily to affected areas during active flare
- Once daily to entire eczema-prone zones
- Twice daily, tapered after symptom control
- Peptides require consistent multi-week use; steroids work faster but don't prevent recurrence
- Skin Barrier Impact
- Neutral to positive. Does not thin epidermis
- Positive. Increases collagen density and lipid synthesis
- Negative. Chronic use causes epidermal atrophy and barrier thinning
- Peptides support barrier integrity; steroids compromise it over time
- Timeframe to Symptom Reduction
- 2–6 weeks for measurable SCORAD improvement
- 4–8 weeks for barrier repair and flare reduction
- 48–72 hours for visible inflammation control
- Steroids deliver fastest symptomatic relief; peptides deliver structural correction
- Recurrence Rate After Stopping
- 30–40% within 6 months if barrier maintenance stops
- 25–35% if ceramide support continues
- 60–75% within 2–4 weeks of discontinuation
- Peptide protocols show lower recurrence when paired with ongoing barrier care